Inozyme Pharma Raises $49M in Series A Financing

Inozyme Pharma, Inc., a Cambridge, MA-based biotechnology company developing novel medicines to treat rare diseases of calcification, affecting soft tissues and bone, raised a $49m in Series A financing.

The round was led by Longitude Capital, and included participation from New Enterprise Associates (NEA), Novo Ventures and Sanofi Ventures.

Founded in 2016 with technology licensed from Yale University, Inozyme Pharma is a biotechnology company committed to developing novel medicines for the treatment of rare diseases characterized by mineral imbalances, which lead to over calcification of soft tissues and under mineralization of bone.
The company intends to use the funds to advance its lead enzyme replacement therapy for the treatment of Generalized Arterial Calcification of Infancy (GACI)* and Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2) into the clinic.

In addition to the financing, the company has also expanded its leadership team, including:
– Axel Bolte, president, chief executive officer, and co-founder
– Henric Bjarke, senior vice president and chief operating officer
– Steven Jungles, senior vice president and chief technical operations officer
– Eric Yuen, senior vice president and chief medical officer
– Ruhi Ahmed, vice president of regulatory and government affairs
– Stephen Basso, vice president of finance
– Joseph Schlessinger, chairman and co-founder, Yale University
– Reinaldo Diaz, Longitude Capital
– Ed Mathers, New Enterprise Associates
– Martin Edwards, Novo Holdings A/S

*GACI is an ultra-rare, autosomal recessive orphan disease affecting infants. It is caused by loss-of-function mutations in either the ENPP1 or ABCC6 gene, and results in low circulating levels of pyrophosphate (PPi) and calcification of medium and large arteries and heart. GACI presents as a crisis within the first week of life and is associated with high mortality rates. The majority of patients are likely to die within the first year of life. If affected children survive past six months, they are likely to continue living but develop ARHR2, a rare skeletal disorder characterized by low levels of serum PPi, which can result in rickets, repeated fractures of the long bones, rachitic skeletal deformities, and impaired growth and development.



Join the discussion